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TCF3-HLF positive leukemia represents a rare subtype of childhood acute lymphoblastic 
leukemia (ALL), characterized by a high rate of treatment failure despite treatment 
intensification and allogeneic stem cell transplantation (SCT). Given the high and 
homogenous expression of CD19 on blast cells of this leukemia subtype, these patients 
may benefit from CD19-directed immunotherapy. Here, we report the experience on nine 
TCF3-HLF positive ALL patients, most of which were treated early in first consolidation 
with blinatumomab as a bridge to SCT between 2015 and 2018. Treatment with 
blinatumomab was generally well tolerated; reversible neurotoxicity was observed in two 
patients. All nine patients achieved molecular remission after blinatumomab treatment, 
seven underwent SCT, for one patient SCT is planned. Median follow-up time after start 
of blinatumomab treatment was 342 days, and four patients remain in molecular 
remission after a follow-up of 1317, 1292, 1245 and 342 days, respectively. Three 
patients died because of infectious complications not directly related to blinatumomab, 
because they occurred after either SCT or emergence of a CD19-negative leukemia 
clone. In light of these encouraging observations, CD19-directed immunotherapy should 
be considered early after induction chemotherapy in TCF3-HLF positive ALL children 
and patients’ outcome monitored systematically by study groups.  
The chromosomal translocation t(17;19), resulting in the oncogenic fusion transcription 
factor TCF3-HLF1, defines a rare cytogenetic subtype of B-cell precursor (BCP) ALL 
occurring in children and young adults that is associated with a dismal outcome2. Major 
leukemia study groups consider TCF3-HLF positive ALL patients eligible for addition of 
experimental therapies in first line. Functional screening of patient-derived xenografts 
revealed a dependence on BCL2 with promising response to a combination of 
venetoclax with vincristine and dexamethasone3, which motivated the inclusion of a 
stratum allowing for combination of venetoclax with standard ALL therapy in the setting 
of a pediatric phase I/II study (NCT03236857)4. Moreover, given the strong 
homogeneous expression of CD19 in TCF3-HLF positive ALL and the impressive 
responses to CD19-directed immunotherapeutic approaches, these patients may benefit 
from CD19-directed immunotherapy5. 
Blinatumomab is a bispecific T-cell engager (BiTE®) antibody simultaneously binding 
CD3-positive cytotoxic T cells and CD19-positive B cells, resulting into a T-cell mediated 
serial lysis of B cells. Based on promising clinical activity with effective responses in 
heavily pretreated patients (NCT01466179)6, blinatumomab gained accelerated 
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approval by the US FDA, EMA and Swissmedic agencies, for treatment of both children 
and adults with relapsed/refractory Philadelphia chromosome-negative BCP-ALL. 
Treatment with blinatumomab in adults with minimal residual disease-positive (MRD+) 
ALL, mostly used as a bridge to stem cell transplantation (SCT), resulted into complete 
molecular response with MRD negativity in 80% of patients7,8. Similarly, high rate of 
molecular remission were confirmed in a larger clinical study enrolling adults patients in 
second or later morphological complete remission (CR)9. Extensive safety and efficacy 
data are available from pediatric patients included into a phase I/II study and an 
expanded access study (RIALTO) at a recommended Phase II dose of 15 µg/m2/day 
continuous infusion (NCT02187354)10. In this first study, treatment of pediatric BCP-ALL 
patients with relapsed/refractory disease was initiated with high disease burden, given 
the endpoint requirements of the trial and only 16/62 patients for which MRD data was 
available achieved molecular CR, with a 24-month Kaplan–Meier estimate for overall 
survival of 25%11. The toxicity profile of blinatumomab is well established, including 
cytokine-release syndrome (CRS) and reversible neurologic events, such as ataxia, 
seizures and encephalopathy. The mechanisms leading to neurotoxicity remain unclear 
and may relate to variable expression of CD19 within the brain. Given the good 
tolerability and promising efficacy data, the potential benefit of blinatumomab improving 
outcome is being investigated in patients experiencing high-risk ALL first relapse 
(NCT02393859) and will be evaluated in first-line treatment in patients with intermediate 
and high-risk BCP-ALL by the AIEOP-BFM study group (NCT02393859).  
Here, we report the European experience with blinatumomab using retrospectively 
collected data from nine patients with TCF3-HLF positive ALL that have been treated 
with blinatumomab between 2015 and 2018 by members of the international BFM study 
group after approval by the competent ethics committee; two of these 9 patients were 
enrolled in the expanded access protocol RIALTO. An overview of the patient data and 
clinical courses is provided in tables 1, 2 and figure 1.  
Blinatumomab was initiated for disease refractory to induction chemotherapy (patient 1), 
for persistent MRD after consolidation chemotherapy (patients 3, 4, 5, 7, 8, 9), and after 
first relapse (patient 2, 6). Blinatumomab was administered at 15 µg/m2/day for two to 
four cycles. All 9 patients responded, obtaining molecular CR after either the first cycle 
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(eight out of nine) or the second cycle (patient 7). Seven out of nine patients underwent 
allogeneic SCT after blinatumomab treatment. Details on the type of donor employed 
are shown in table 2. Four patients developed mild to moderate acute graft-versus-host 
disease (GvHD). No suitable donor could be found in time for patient 5, and this patient 
relapsed with CD19-negative leukemia blasts. 
Four patients achieved a long-term remission and are still MRD negative after a follow-
up of 1317, 1292, 1245 and 342 days, respectively (Figure 1). Given the expected risk 
for subsequent relapse, additional therapy was provided after SCT with one (patient 4) 
or two cycles (patients 2, 3) of blinatumomab. Three patients died from infectious 
complications: patient 4 due to a transplant-related adenoviral infection whilst in second 
molecular remission after her second SCT, patient 5 from a fungal infection whilst in 
CD19-negative relapse, and patient 6 from transplant-related aspergillus infection while 
in molecular relapse. Significant neurotoxicity occurred in two patients (Patients 1, 4). 
For patient 1, blinatumomab had to be interrupted due to confusion and decreased level 
of consciousness lasting 24 hours; it was resumed with a reduced dose of 5 µg/m2/day 
and finally stopped because of seizures. This patient is currently still in molecular 
remission after SCT. Similar complications have been previously reported in pediatric 
patients12,13. Disseminated intravascular coagulation (DIC) was reported during 
treatment in two patients with overt leukemia, but was not considered to be treatment-
related, because TCF3-HLF positive leukemia often present with coagulopathies. Patient 
9 developed grade 2 CRS lasting for 48 hours. No other significant toxicity was reported. 
This is the first report of clinical activity of CD19-directed immunotherapy in TCF3-HLF 
positive ALL, a rare BCP-ALL subtype reported to be almost always fatal even with most 
intensive conventional treatment regimens2. Although the number of patients treated is 
small and follow-up time limited, these results provide a strong rational for rapid 
intervention with immunotherapy for this ALL subtype. The response to blinatumomab 
has been reported to be less effective in patients with higher disease burden suggesting 
that this approach may be more effective in the MRD setting6. Current ongoing 
randomized pediatric studies will hopefully provide more evidence to answer this 
question. Until then, we recommend using a different treatment modality to reduce the 
leukemia burden before initiating blinatumomab. A conventional cytoreduction will also 
be required if immunotherapy with autologous CAR-T cell would be considered, allowing 
lymphapheresis and CAR-T cell manufacturing. Based on the current evidence, 
blinatumomab appears to be a promising therapeutical element to improve the quality of 
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remission in TCF3-HLF positive BCP-ALL patients as a bridge to SCT. In contrast, CAR-
T might provide an attractive stand-alone treatment for definitive therapy without SCT. In 
general, this approach will have to be validated in clinical studies. Given the strong 
preclinical evidence for sensitivity to the BCL2 inhibitor venetoclax in most cases, 
including relapsing patients, combination of venetoclax with standard ALL chemotherapy 
may provide an additional treatment element improving outcome of these patients. 
Patients could be evaluated by functional screening using drug response profiling3,14 and 
BH-3 profiling15 at diagnosis. Three patients in this cohort have received additional 
courses of blinatumomab post-transplant for further consolidation of the leukemia 
remission, since even with MRD negative remissions prior to and after allogeneic HSCT, 
relevant rates of subsequent relapses are observed in TCF3-HLF positive ALL2. 
Persisting clones in compartments other than bone marrow may not be covered by MRD 
quantification but still be responsive to blinatumomab therapy. The responses detected 
in this TCF3-HLF positive ALL cohort are encouraging and suggest that the application 
of immunotherapy prior to extensive clonal selection secondary to intensive 
chemotherapy may be beneficial. We need to wait further maturation of the data to 
assess the true value of this approach. The benefit of adding blinatumomab to front-line 
ALL chemotherapy will be addressed in an international prospective clinical trial 
(NCT03643276). Taken together, our results indicate that immunotherapy may improve 
the outcome of TCF3-HLF positive ALL.  
 6 
Acknowledgments 
The authors thank Yun Huang (University Children’s Hospital Zurich) for careful review 
of the manuscript and Renate Siegenthaler (University Children’s Hospital Zurich) to 
provide data. 
 
Authorship 
Contribution: B.M. and JP.B. designed and performed the research, analyzed the data, 
and wrote the paper; L.V., P.A., N.B., B.B., C.CS., S.E., V.H., J.K., J.S., A.V., Y.Y., S.A., 
A.B., F.L., A.v.S., M.S. JP.B. managed treatment, provided data and reviewed the 
manuscript; G.C. A.M. and M.Sch. provided data and reviewed the manuscript; all 
authors read and approved the final manuscript.  
Conflict-of-interest disclosure: A.v.S. has received honoraria for invited presentations 
and has participated at advisory boards organized by Amgen, and has participated at 
advisory boards of the companies Novartis, Pfizer, Roche, Jazz-Pharmaceuticals and 
Morphosys. F.L. has received honoraria for invited presentations and has participated at 
advisory boards organized by Amgen. The other authors declare no competing financial 
interests. 
Correspondence: Jean-Pierre Bourquin, Division of Oncology, University Children’s 
Hospital Zurich, Children’s Research Center, Steinwiesstrasse 75, CH-8032 Zurich, 
Switzerland; e-mail: jean-pierre.bourquin@kispi.uzh.ch . 
 
 7 
References 
 
1. Inaba T, Roberts WM, Shapiro LH, et al. Fusion of the leucine zipper gene HLF to 
the E2A gene in human acute B-lineage leukemia. Science. 1992;257(5069):531–
534.  
2. Minson KA, Prasad P, Vear S, et al. t(17;19) in Children with Acute Lymphocytic 
Leukemia: A Report of 3 Cases and a Review of the Literature. Case Rep 
Hematol. 2013;2013(4):563291–563294.  
3. Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-
HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns 
and therapeutic options. Nat Genet. 2015;47(9):1020–1029.  
4. Place AE, Goldsmith K, Bourquin J-P, et al. Accelerating drug development in 
pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory 
malignancies. Future Oncol. 2018;14(21):2115-2129.  
5. Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological 
malignancies with bispecific antibodies. Blood. 2018;131(1):30–38.  
6. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for 
adult patients with relapsed or refractory B-precursor acute lymphoblastic 
leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 
2015;16(1):57–66.  
7. Topp MS, Kufer P, Gökbuget N, et al. Targeted Therapy With the T-Cell–Engaging 
Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in 
B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response 
Rate and Prolonged Leukemia-Free Survival. J Clin Oncol. 2011;29(18):2493–
2498.  
8. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic 
relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in 
B-lineage ALL. Blood. 2012;120(26):5185–5187.  
9. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual 
disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 
2018;131(14):1522–1531.  
10. Stackelberg von A, Locatelli F, Zugmaier G, et al. Phase 1/2 Study in Pediatric 
Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic 
Leukemia (BCP-ALL) Receiving Blinatumomab Treatment. Blood. 
2014;124(21):2292.  
 8 
11. Gore L, Locatelli F, Zugmaier G, et al. Survival after blinatumomab treatment in 
pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic 
leukemia. Blood Cancer J. 2018;8(9):80.  
12. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after 
blinatumomab treatment related to abnormal macrophage activation and 
ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–5157.  
13. Stackelberg von A, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of 
Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute 
Lymphoblastic Leukemia. J Clin Oncol 2016;34(36):4381–4389.  
14. Frismantas V, Dobay MP, Rinaldi A, et al. Ex vivo drug response profiling detects 
recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. 
Blood. 2017;129(11):e26–e37.  
15. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 Profiling 
Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-
737 and Conventional Chemotherapeutic Agents. Cancer Cell. 2007;12(2):171–
185.  
Table 1: Clinical data of 9 patients with TCF3-HLF positive ALL treated with 
blinatumomab. 
 
N
o. 
Induction Treatment     Blinatumomab Treatment  
 Ag
e 
(y) 
Se
x 
WBC 
(nL) 
Calciu
m 
(mmol/
L) 
EM
D 
Treatme
nt 
Protocol 
Pred
nison
e 
Resp
onse 
Disease 
Burden 
post 
induction 
Disease 
Status 
prior to 
Blina 
Disease 
Involvm
ent 
SAEs Mole
cular 
Remi
ssion
5 
1 13 F 13.8 2.42 No
ne 
AALL 
1131 
N/A FACS 
27.5% 
RD BM Depres
sed 
LOC 
Yes 
2 14 F 6.15 3.65 No
ne 
AIEOP-
BFM 
PPR < 10-3 > 10-
4 
Relapse BM Bilatera
l hip 
osteon
ecrosis 
Yes 
3 8 M 14.4
9 
2.57 CN
S2
b 
AIEOP-
BFM 
PGR 10-2 MRD BM None Yes 
4 7 F 5.26 3.2 CN
S3 
AIEOP-
BFM 
PGR 6 x 10-4 MRD BM Convul
sion 
CNS 
pleocyt
osis2 
Yes 
5 10 M 4.6 2.46 No
ne 
FRALLE PGR 5 x 10-4 MRD BM None Yes 
6 3 F N/A N/A CN
S2 
AIEOP-
BFM 
PGR negative Relapse4 BM None Yes 
7 8 F 11.3 N/A No
ne 
AIEOP-
BFM 
PGR 7.5 x 10-3 MRD BM None Yes 
8 5 F 25.7 2.63 No
ne 
UKALL N/A 3x 10-5 MRD BM None Yes 
9 7 M 8.2 5.03 No
ne 
AIEOP-
BFM 
PGR 3.2 x 10-3 MRD BM CRS Yes7 
 
EMD, extramedullary disease; RD, refractory disease; BM, bone marrow; SAE, serious 
adverse events; LOC, loss of consciousness; CRS, Cytokine Release Syndrome 
 
1: CNS pleocytosis without disease involvement  
2: Initial diagnosis was c-ALL, isolated relapse under maintenance TCF3-HLF positive  
3: Molecular Remission defined as per supplemental table 1  
4: One marker positive non quantifiable, one marker negative after one cycle 
blinatumomab 
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Table 2: Definitive treatment of 9 patients with blinatumomab and outcome 
 
No. HSCT    Current 
status 
FU 
time (d)6 
 Donor type 
for HSCT 
Conditioning GvHD 
Prophylaxis 
GvHD   
1 Matched 
Unrelated 
Bu, Thiotepa, 
Cy 
CsA Mild 
GvHD 
ACR 1317 
2 Matched 
Unrelated1 
By, Cy, VP16, 
Thymoglobulin 
CsA Mild 
GvHD 
ACR 1292 
3 Matched 
Unrelated 
TBI, VP16, 
ATG 
CsA, MTX Moderate 
GvHD 
ACR 1245 
4 Haploidentical3 Melphalan, 
Thiotepa, 
Fludarabine 
Alemtuzumab, 
MM 
No Died from 
infection 
under remission 
363 
5 No HSCT – – – Died from 
infection 
under CD19-neg. 
relapse 
210 
6 Matched 
Related 
TBI, VP16 CsA, MTX Moderate 
GvHD 
Relapse; Died 
from 
infection after 
HSCT 
120 
7 Haploidentical TBI, Thiotepa, 
Fludarabine 
None No ACR 342 
8 Matched 
Unrelated 
TBI, Cy Alemtuzumab, 
CsA, MTX 
No ACR 160 
9 No HSCT – – – ACR 79 
 
MM, mycophenolate mofetil; ACR, alive and in complete remission 
 
1: Patient underwent prior transplantation after induction but relapsed shortly after  
2: Patient underwent prior transplantation after 2 cycles blinatumomab, but relapsed 
shortly after  
3: Follow-up since first day of blinatumomab treatment  
  
Figure 1: Time course of 9 patients with TCF3-HLF positive ALL treated with 
blinatumomab. 
 
REL, relapse; VCR, vincristine; Mitox, mitoxantrone; BTZ, bortezomib; VTX, venetoclax; 
DAS, dasatinib; INO, inotuzumab 
 

Supplemental Table 1: Quantitative and Sensitivity Ranges of MRD markers, GvHD classification and additional clinical information.
Marker 1 Marker 2 Marker 3 Marker 1 Marker 2 Marker 3 Cycle 1 Cycle 2 Cycle 3 Cycle 4
Patient 1 5x 10
-4
5x 10
-4
5x 10
-4
1x 10
-4
1x 10
-4
1x 10
-4 chronic Yes FISH 91 d1-d7: 5 µg, then 15 µg 5 µg – – – –
Patient 2 1x 10
-4
1x 10
-4 – 1x 10
-4
1x 10
-4 – acute Yes FISH 1292 d1-d7: 5 µg, then 15 µg 15 µg 15 µg – – –
Patient 3 1x 10
-3
5x 10
-4 – 5x 10
-4
1x 10
-5 – chronic – FISH (Cytocell) 489 15 µg 15 µg 7.5 µg 15 µg – –
Patient 4 1x 10
-4
1x 10
-4 – 1x 10
-4
1x 10
-5 – – – FISH (Cytocell) – 15 µg 15 µg 15 µg – positive unchanged
Patient 5 1x 10
-4 – – 1x 10
-5 – – – – RT-PCR – 15 µg 15 µg 15 µg – negative not performed
Patient 6 1x 10
-4
1x 10
-4 – 1x 10
-5
1x 10
-5 – acute – RT-PCR and FISH – 15 µg – – – positive unchanged
Patient 7 1x 10
-4
1x 10
-4 – 1x 10
-5
1x 10
-5 – – – RT-PCR
1 300 15 µg 15 µg – – – –
Patient 8 1x 10
-4
1x 10
-4 – 1x 10
-4
1x 10
-4 – – – FISH (Cytocell) 50 15 µg 15 µg – – – –
Patient 9 1x 10
-4
5x 10
-4 – 1x 10
-5
1x 10
-4 – – – RT-PCR
1 71 15 µg 15 µg – – – –
RIALTO, Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (NCT02187354)
1: RT-PCR reference: van der Velden VH, et al. Leukemia. 2007 Apr;21(4):706-13
Cytogenetics 
at relapse
No. GvHD 
classification
RIALTO CD19 status 
at relapse
Molecular
Diagnostic
Last MRD 
date (days 
post blina)
Blinatumomab Dosage
(/m
2
*d)
Quantitative
Range
Sensitivity
Range
